Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
- PMID: 16219666
- DOI: 10.1152/ajpendo.00326.2004
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Abstract
Among the products of enteroendocrine cells are the incretins glucagon-like peptide-1 (GLP-1, secreted by L cells) and glucose-dependent insulinotropic peptide (GIP, secreted by K cells). These are key modulators of insulin secretion, glucose homeostasis, and gastric emptying. Because of the rapid early rise of GLP-1 in plasma after oral glucose, we wished to definitively establish the absence or presence of L cells, as well as the relative distribution of the incretin cell types in human duodenum. We confirmed the presence of proglucagon and pro-GIP genes, their products, and glucosensory molecules by tissue immunohistochemistry and RT-PCR of laser-captured, single duodenal cells. We also assayed plasma glucose, incretin, and insulin levels in subjects with normal glucose tolerance and type 2 diabetes for 120 min after they ingested 75 g of glucose. Subjects with normal glucose tolerance (n=14) had as many L cells (15+/-1), expressed per 1,000 gut epithelial cells, as K cells (13+/-1), with some containing both hormones (L/K cells, 5+/-1). In type 2 diabetes, the number of L and L/K cells was increased (26+/-2; P<0.001 and 9+/-1; P < 0.001, respectively). Both L and K cells contained glucokinase and glucose transporter-1, -2, and -3. Newly diagnosed type 2 diabetic subjects had increased plasma GLP-1 levels between 20 and 80 min, concurrently with rising plasma insulin levels. Significant coexpression of the main incretin peptides occurs in human duodenum. L and K cells are present in equal numbers. New onset type 2 diabetes is associated with a shift to the L phenotype.
Similar articles
-
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.Diabetes. 2008 Mar;57(3):678-87. doi: 10.2337/db07-1124. Epub 2007 Dec 5. Diabetes. 2008. PMID: 18057091
-
Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.Regul Pept. 2004 Nov 15;122(3):209-17. doi: 10.1016/j.regpep.2004.06.020. Regul Pept. 2004. PMID: 15491793
-
Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.Am J Physiol Endocrinol Metab. 2005 Sep;289(3):E504-7. doi: 10.1152/ajpendo.00099.2005. Epub 2005 May 10. Am J Physiol Endocrinol Metab. 2005. PMID: 15886226 Clinical Trial.
-
[Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].Ned Tijdschr Geneeskd. 2004 Sep 25;148(39):1912-7. Ned Tijdschr Geneeskd. 2004. PMID: 15495988 Review. Dutch.
-
Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.Exp Clin Endocrinol Diabetes. 1997;105(4):187-95. doi: 10.1055/s-0029-1211750. Exp Clin Endocrinol Diabetes. 1997. PMID: 9285204 Review.
Cited by
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.Drug Des Devel Ther. 2016 May 9;10:1619-26. doi: 10.2147/DDDT.S105021. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27274195 Free PMC article.
-
Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways.Front Cell Neurosci. 2016 Sep 12;10:214. doi: 10.3389/fncel.2016.00214. eCollection 2016. Front Cell Neurosci. 2016. PMID: 27672360 Free PMC article.
-
Short-chain fatty acids in control of body weight and insulin sensitivity.Nat Rev Endocrinol. 2015 Oct;11(10):577-91. doi: 10.1038/nrendo.2015.128. Epub 2015 Aug 11. Nat Rev Endocrinol. 2015. PMID: 26260141 Review.
-
Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?Diabetologia. 2009 Nov;52(11):2270-2276. doi: 10.1007/s00125-009-1511-8. Epub 2009 Sep 1. Diabetologia. 2009. PMID: 19727661
-
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date.Diabetes Metab Syndr Obes. 2019 Dec 2;12:2515-2529. doi: 10.2147/DMSO.S229802. eCollection 2019. Diabetes Metab Syndr Obes. 2019. PMID: 31819577 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases